Pharmaceutical Executive July 16, 2025
A proactive strategy that promotes U.S. pharmaceutical manufacturing is a crucial pillar within a resilient and diversified supply chain ecosystem.
Drug shortages in the United States hit an all-time high last year. President Trump has signaled pharmaceutical tariffs as a way to incentivize American manufacturing, saying “the pharmaceutical companies are going to come roaring back.”1 But tariffs alone are unlikely to catalyze U.S. production at scale, especially for generic drugs, which account for 90% of American prescriptions. U.S. manufacturing also won’t singlehandedly secure shortage-prone drug supply chains. To ensure a reliable supply of medicines, the United States must enable integrated, agile, and diversified manufacturing ecosystems––including across borders.
What impact will tariffs have on the pharmaceutical industry?
Globalization of pharmaceutical...
Today's Sponsors
Today's Sponsor